Frequently Asked Questions
The global RNA/DNA extraction kit market was valued at USD 1.5 Billion in 2022.
The RNA/DNA extraction kit market is anticipated to grow at a CAGR of 7.9% between 2023 and 2030, reaching USD 2.55 Billion in 2030.
Cell-free DNA is the leading segment by product, holding over 35% share in terms of value in 2022.
The hospital segment governs the demand for RNA/DNA extraction kits worldwide, holding a massive share of over 38% in 2022.
The hospital segment will post the highest CAGR during the forecast period.
North America is fuelling the growth of the RNA/DNA extraction kit industry, with an over 42% share in 2022.
The top players include Roche Holding AG, Promega Corporation, Merck & Co. Inc, and Qiagen. Other major players include ThermoFisher Scientific Inc, Agilent Technologies, Bio-Rad Laboratories Inc, and bioMérieux S.A.
The growing demand for genetic testing and molecular diagnostics, developments in molecular biology techniques, and a growing emphasis on personalized medicine and precision medicines are the primary market drivers of the RNA/DNA extraction kit industry.
The major market restraints of the RNA/DNA extraction kit industry include stringent regulatory requirements, high costs associated with advanced extraction technologies, and challenges in sample preparation and handling.
The rising adoption of liquid biopsy techniques, increased R&D activities in genomics and genetic testing, and expanding applications in infectious disease diagnosis, cancer profiling, and pharmacogenomics are the major market opportunities for the RNA/DNA extraction kit industry.